TheEdgeResearch
Home / Stocks / QLINEA.ST

Q-linea AB (publ) (QLINEA.ST)

STO Healthcare Medical - Specialties
$17.90 ▲ +1.13%
Market Cap
$119.2M
Sector
Healthcare
Industry
Medical - Specialties
Beta
0.59
52-Wk Range
14.55-38.425
CEO
Stuart Gander
Country
SE
Currency
SEK

Q-linea AB (publ) operates in the Medical - Specialties industry of the Healthcare sector, headquartered in Uppsala, UP, SE. The stock last traded at $17.90, up 1.13% on the session, giving a market capitalisation of $119.2M. Its beta of 0.59 implies it has historically moved less than the broad market.

Company profile
Exchange
Stockholm Stock Exchange
Employees
70
IPO date
2018-12-07
Headquarters
Uppsala, UP, SE
About Q-linea AB (publ)

Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the Frozen insert. The company also develops Podler, a portable blood culture technology. It serves physicians, hospitals, laboratories, healthcare payers, and the medical profession. The company was incorporated in 2007 and is headquartered in Uppsala, Sweden.

Comparable companies

Q-linea AB (publ) is most often compared with the following Healthcare names:

ACUC.STALZ.STBRAIN.STERMA.STINTEG-B.STIZAFE-B.STKLAR.STNEOLA.STNOSA.STSENZA.ST
More research on QLINEA.ST
QLINEA.ST technical analysis QLINEA.ST TheEdge Score Compare against peers
Open full interactive analysis & DCF →